Further 'Slight Modifications' To Advisory Panel Process Likely
This article was originally published in The Gray Sheet
FDA's device center said it will continue to assess its advisory panel process, a week after the first two meetings were held without the traditional up-or-down vote on device approvability
You may also be interested in...
FDA advisory panel members will no longer take an up or down vote on the approvability of medical devices, or on recommended conditions of approval, CDRH announced April 26
Liquid biopsy start-up Grail Inc. announced that a study of almost 6,700 participants found that its blood test could detect more than 50 types of cancer with a low false-positive rate. See what Minetta Liu, study co-lead author and a Mayo Clinic professor of oncology, had to say about the research.
Sanofi’s next-generation meningococcal vaccine, broader use of Bristol-Myers Squibb’s Reblozyl move toward approval; United Therapeutics foreshadows Trevyent regulatory difficulties.